Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study.
Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group. Porreca A, et al. Health Qual Life Outcomes. 2018 Jun 13;16(1):122. doi: 10.1186/s12955-018-0952-5. Health Qual Life Outcomes. 2018. PMID: 29898750 Free PMC article.
Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study).
Antonelli A, Palumbo C, Noale M, Artibani W, Bassi P, Bertoni F, Bracarda S, Bruni A, Corvò R, Gacci M, Magrini SM, Montironi R, Porreca A, Tubaro A, Zagonel V, Maggi S; Pros-IT CNR study group. Antonelli A, et al. Minerva Urol Nefrol. 2020 Oct;72(5):595-604. doi: 10.23736/S0393-2249.19.03637-3. Epub 2020 Jan 7. Minerva Urol Nefrol. 2020. PMID: 31920063 Free article.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Bracarda S, et al. Among authors: bortolus r. Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3. Future Oncol. 2014. PMID: 24295376 Clinical Trial.
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Veccia A, et al. Among authors: bortolus r. Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18. Future Oncol. 2016. PMID: 26776493
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, Monari F, Procopio G, Santini D, Seregni E, Valdagni R. Baldari S, et al. Among authors: bortolus r. Crit Rev Oncol Hematol. 2017 May;113:43-51. doi: 10.1016/j.critrevonc.2017.03.001. Epub 2017 Mar 6. Crit Rev Oncol Hematol. 2017. PMID: 28427521 Review.
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Caffo O, Frantellizzi V, Tucci M, Galli L, Monari F, Baldari S, Masini C, Bortolus R, Facchini G, Alongi P, Agostini S, Zichi C, Biasco E, Fanti S, Pignata S, Filice A, Borsatti E, Rossetti S, Spada M, Cortesi E, De Vincentis G. Caffo O, et al. Among authors: bortolus r. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2633-2638. doi: 10.1007/s00259-020-04796-w. Epub 2020 Apr 5. Eur J Nucl Med Mol Imaging. 2020. PMID: 32249345
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2.
Caffo O, Zagonel V, Baldessari C, Berruti A, Bortolus R, Buti S, Ceresoli GL, Donini M, Ermacora P, Fornarini G, Fratino L, Masini C, Massari F, Mosca A, Mucciarini C, Procopio G, Tucci M, Verri E, Zucali P, Buttigliero C. Caffo O, et al. Among authors: bortolus r. Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18. Ann Oncol. 2020. PMID: 32562741 Free PMC article. No abstract available.
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer.
Caffo O, Gasparro D, Di Lorenzo G, Volta AD, Guglielmini P, Zucali P, Bortolus R, Cavo A, Ceresoli G, Chiari R, Fornarini G, Fratino L, Iaculli A, Maruzzo M, Masini C, Morelli F, Mucciarini C, Procopio G, Sabbatini R, Verri E, Kinspergher S, Maines F, Messina C, Veccia A, Donini M. Caffo O, et al. Among authors: bortolus r. Eur J Cancer. 2020 Nov;140:140-146. doi: 10.1016/j.ejca.2020.09.018. Epub 2020 Oct 20. Eur J Cancer. 2020. PMID: 33091718 Free PMC article.
115 results